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Abstract
Although it is known that individuals living with HIV have a higher HPV prevalence, the
impact of individual HPV types on HIV acquisition is less clear. In this prospective cohort
study we investigated the relationship between HPV types and incident HIV infection among
men who have sex with men (MSM) and transgender women (TW) in Lima, Peru. Six hundred HIV-negative Peruvian MSM and TW participated in a 2-year study with biannual visits.
At baseline, participants completed a computerized, self-administered questionnaire on sexual behavior and HPV knowledge and underwent a physical exam including anogenital
swabs for HPV DNA (37 genotypes via linear array testing) and HIV testing; follow-up visits
included the questionnaire and HIV testing. Participant mean age was 25 years (range =
18–40), with 48.9% self-identifying as gay and 86.5% reporting having sex exclusively with
men. At baseline, 530 participants had HPV DNA present (61.1% with high-risk HPV, 84.9%
with low-risk HPV). Among 571 participants who returned for any study visit, 73 (12.8%)
became infected with HIV during the 2-year follow-up (6% HIV incidence). Compared to
those without HIV, more participants with HIV had any HPV type present (97.3% vs. 87.6%,
respectively, p = .01), more than one HPV type (79.5% vs. 58.2%, p < .01), or high-risk HPV
(72.6% vs. 51.4%, p < .01). Some participants lost to follow-up could have been HIV-positive, which would have affected the relationship of HPV and HIV infection. Our prospective
study showed that participants with any HPV type, more than one HPV type, or high-risk
HPV were more likely to test positive for HIV. Although most studies have shown HPV–HIV
coinfection, our findings illustrate the strong relationship between individual HPV types and
HIV infection. This further illustrates the potential utility of HPV vaccine for MSM and TW,
not only for HPV prevention but also possibly for HIV prevention.
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Introduction
The association of many sexually transmitted infections (STIs) with HIV acquisition among
men who have sex with men (MSM) and transgender women (TW) is well established [1–3].
Testing and treatment of ulcerative STIs, in particular, is a core element of HIV prevention programs in these populations [4]. Human papillomavirus (HPV) is the most prevalent STI worldwide among all sexually active adults and affects approximately 50% of HIV-negative MSM,
which may include TW because the groups are often erroneously combined [5]. Although HPV
is independently associated with HIV infection in MSM [6,7] (data unavailable for TW), little is
known about the relationship between specific HPV types and incident HIV infection [6].
Most new HIV infections in Latin America occur among MSM and TW, with transmission
mainly occurring during unprotected anal intercourse [1,8]. In Peru, the HIV prevalence for
MSM is 9.5%–10.5% [9,10], whereas the prevalence for TW is even higher, at 30% [11], far
exceeding the 0.3% infection rate found in the general population (adults aged 15–49 years) [12].
Several studies have shown that high-risk HPV (HRHPV) infection and prevalence of multiple HPV types is higher among HIV-positive MSM compared to HIV-negative MSM [13,14].
Estimates of HPV prevalence in the anal canal are particularly high among MSM in Peru,
ranging from 77% to 97% [14,15].
One study in Peru showed HIV-positive MSM were coinfected with twice as many HPV
types as their HIV-negative counterparts [15]. Because some chronic infections with HPV can
be prevented with HPV vaccination, it is possible that HPV vaccination could also be promoted as part of additive HIV prevention interventions.
Although several studies have investigated HIV and HPV coinfection, a growing body of
research suggests that HPV infection is implicated in the acquisition of HIV [6,7,16]. This
study explored the relationship between HPV infection and HIV acquisition by specifying the
HPV types associated with incident HIV infection among all participants in a prospective
cohort of MSM and TW in Lima, Peru.

Methods
MSM and TW were recruited for a cohort study examining the relationship between anogenital warts and HIV acquisition [17,18]. The protocol for this study is described in detail elsewhere [19]. Briefly, the study site was Epicentro Salud, a local community-based health center
for MSM and TW. Study participants were recruited at Epicentro Salud, bars, clubs, and volleyball courts, via social media, and by snowball sampling. Inclusion criteria were: born
anatomically male, aged 18–40 years, HIV-negative, had anal intercourse with a male in the
past 12 months, resident of metropolitan Lima, and willing to provide blood samples and anal
swabs. Participants were excluded if they were HIV positive, participated in an HIV or HPV
clinical trial, had a known immunodeficiency disorder, or if they self-reported use of pre-exposure prophylaxis (PrEP). Participants were not excluded by AGW status.
Participants completed a computerized, self-administered questionnaire in which they were
asked whether they experienced any symptoms of anal bleeding, anal pain or burning, anal
ulcers, or sores during the prior 6 months. Next, sociobehavioral questions were asked, including usual sexual role when having sex with a man, age at first anal intercourse, and number of
instances of anal intercourse in the prior 6 months. We assessed condom use during the prior 6
months and during participants’ most recent anal sex with a man. Following the questionnaire,
participants underwent a physical exam to check for signs of anogenital warts. If the presence of
anogenital warts was unclear, biopsies were performed to confirm whether they were present.
Participants were followed at 6, 12, 18, and 24 months post-enrollment for HIV testing and
self-administered sociobehavioral interviews. HIV status was assessed using the Determine
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HIV-1/2 Combo Ag/Ab test and confirmed by indirect immunofluorescence assay (in-house
testing at Peruvian National Institute of Health) at each visit. Referrals for care and treatment
were made as necessary.

Laboratory assays for HPV
Following previously established protocols, anogenital specimens were collected at the baseline
visit using prewetted Dacron swabs from the coronal sulcus or glans penis, penile shaft, anus,
and scrotum, combined into one sample per participant, and stored at -80˚C [20]. DNA was
extracted at the Moffitt Cancer Center (in Tampa, FL) using the QIAamp Media MDx Kit, followed by polymerase chain reaction and HPV genotyping. Samples positive for β-globin or at
least one HPV genotype were considered adequate and included in the analysis (overall β-globin positivity = 98%). The Roche Linear Array assay was used to detect 37 HPV genotypes classified as high risk (oncogenic; HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 68) or low
risk (nononcogenic; HPV 6, 11, 26, 40, 42, 53, 54, 55, 61, 62, 64, 66, 67, 69, 70, 71, 72, 73, 81,
82, 82 subtype IS39, 83, 84, and 89 [formerly CP6108]) [21]. The genotypes were further classified into HPV9 vaccine genotypes (i.e., 6, 11, 16, 18, 31, 33, 45, 52, and 58).

Statistical analyses
HIV status and dichotomized HRHPV genotypes, HPV9 vaccine genotypes, and HP4 vaccine
genotypes were examined for explanatory relationships between HPV and HIV. In bivariate
analysis, categorical variables were assessed using chi-square or trend tests (Mantel-Haenszel
chi-square test), whereas continuous variables were assessed using Wilcoxon rank-sum tests.
Logistic regression was used to construct multivariate analysis models. Each theoretically plausible independent variable significant at p < .10 in the bivariate analysis was entered into the
model using backward selection. These included experiencing anal bleeding during the prior 6
months, experiencing anal ulcers during the prior 6 months, usual sexual role, and sexual identity. The first variable accounting for maximum variation in the model was selected, and subsequent variables were added until there was no significant variation in the prediction of the
outcome variable to obtain the most parsimonious model. Missing data were excluded from
our primary analysis. We performed a sensitivity analysis by replacing missing data by the
mean or highest occurrence, and controlled for missing dummy variables in the regression
model. The results were consistent with our primary analysis. Models were adjusted for demographic variables (i.e., age and education level). Statistical significance was set at p < .05 and
adjusted odds ratios (AORs) were reported using Stata 14.0 software. In the original sample
size calculation of 600 participants, a sample size of 264 MSM in each group provided 80%
power to detect an 8% difference in HIV incidence (15% among those with AGW, and 7%
among those without AGW; Hazard Ratio: 2.1; with a type I error of 0.05). We expected 13%
loss to follow-up; therefore, 300 subjects in each group were needed.
All participants provided written informed consent to participate in this study, which took
place between February 15, 2012 and September 27, 2015. This study was approved by institutional review boards at the University of California, Los Angeles in the United States and
Impacta Salud y Educación in Lima, Peru.

Results and discussion
Of 756 individuals screened for potential participation, 156 were excluded due to HIV infection at baseline. Among the 600 initially HIV-negative participants, 571 completed the final
visit at month 24 and had an HIV test result (Table 1). The denominators for each variable are
different due to missing data. A total of 453 reported the sex of their partners in the past 6
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Table 1. Comparison of characteristics among Peruvian MSM and TW with and without HIV at month 24 (N = 571).
Total
n (%)

HIV-Positive
n (%)

HIV-Negative
n (%)

571 (100)

73 (12.8)

498 (87.2)

18–24

225 (46.9)

34 (51.5)

191 (46.1)

25–29

141 (29.4)

24 (36.4)

117 (28.3)

30+

114 (23.8)

8 (12.1)

106 (25.6)

Secondary or less

271 (47.5)

34 (46.6)

237 (47.6)

Tertiary or university

300 (52.5)

39 (53.4)

261 (52.4)

Yes

122 (31.3)

22 (44.0)

100 (29.4)

No

268 (68.7)

28 (56.0)

240 (70.6)

Yes

54 (12.9)

12 (27.9)

42 (11.2)

No

364 (87.1)

31 (72.1)

333 (88.8)

Yes

22 (5.1)

7 (12.3)

15 (4)

No

411 (94.9)

50 (87.7)

361 (96)

Yes

206 (30.1)

31 (42.5)

175 (35.1)

No

365 (63.9)

42 (57.5)

323 (64.9)

Heterosexual

54 (9.5)

7 (9.7)

47 (9.5)

Homosexual

277 (48.9)

39 (54.2)

238 (48.2)

Bisexual

141 (24.9)

21 (29.2)

120 (24.3)

94 (16.6)

5 (6.9)

89 (18)

< 14

105 (18.4)

10 (13.7)

95 (19.1)

14–19

340 (59.5)

50 (68.5)

290 (58.2)

> 19

126 (22.1)

13 (17.8)

113 (22.7)

8 (4–20)

10 (3–20)

7 (4–20)

Yes

295 (72.7)

35 (61.4)

260 (74.5)

No

111 (27.3)

22 (38.6)

89 (25.5)

Men only

394 (87)

58 (90.6)

336 (86.4)

Men and women only

59 (13)

6 (9.4)

53 (13.6)

Insertive only or mostly

112 (24.6)

9 (14.3)

103 (26.3)

Receptive only or mostly or equally insertive and receptive

343 (75.4)

54 (85.7)

289 (73.7)

Characteristics
Overall
Age

p

.039

Education

.871

Current STI symptoms

.038

Anal bleeding, last 6 months

.005

Anal ulcers or sores, last 6 months

.016

Current anogenital warts

.224

Sexual identity

a

Transgender

.127

Age at first anal intercourse

Instances of anal sex, last 6 monthsb

.272

Condom used, last anal sex with a man

.599
.040

Sex of partners, last 6 months

.349

Sexual role

.040

Sex and alcohol, past month

.654

Yes

145 (30.5)

18 (28.1)

127 (30.9)

No

330 (69.5)

46 (71.9)

284 (69.1)

Yes

26 (5.6)

4 (6.3)

22 (5.5)

No

439 (94.4)

60 (93.7)

379 (94.5)

Sex and drugs, past month

.876

Transactional sex

.486
(Continued)
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Table 1. (Continued)
Characteristics

Total
n (%)

HIV-Positive
n (%)

HIV-Negative
n (%)

Yes

14 (28.0)

1 (50.0)

13 (27.1)

No

36 (72.0)

1 (50.0)

35 (72.9)

Yes

507 (88.8)

71 (97.3)

436 (87.6)

No

64 (11.2)

2 (2.7)

62 (12.5)

Yes

309 (54.1)

53 (72.6)

256 (51.4)

No

262 (45.9)

20 (27.4)

242 (48.6)

Yes

432 (75.7)

58 (79.5)

374 (75.1)

No

139 (24.3)

15 (20.5)

124 (24.9)

Yes

24 (4.2)

2 (2.7)

22 (4.4)

No

547 (95.8)

71 (97.3)

476 (95.6)

Yes

105 (18.6)

20 (28.2)

85 (17.2)

No

459 (81.4)

51 (71.8)

408 (82.8)

Yes

201 (35.6)

34 (47.9)

167 (33.9)

No

363 (64.4)

37 (52.1)

326 (66.1)

Any HPV Present

p

.014

At least one HRHPV

.001

At least one low-risk HPV

.418

Circumcised

.505

HPV DNA 16, 18c

.027

HPV DNA 16, 18, 31, 33, 35, 52, 58c

.021

a

At the time of the survey we included transgender as a sexual identity.
Figures reflect median (interquartile range).

b
c

Presence of any of the listed genotypes.

https://doi.org/10.1371/journal.pone.0204996.t001

months, of whom 87% (394) reported having sex exclusively with men and 48.9% (277) selfidentified as homosexual. Of the 566 participants who self-reported their sexual identity, 472
(83.4%) were MSM (heterosexual, homosexual, bisexual); the remainder were TW. Visible
anogenital warts were noted for 233 participants at baseline (60% anal only). Participant mean
age was 25 years (range = 18–40). At baseline, 530 participants had any HPV DNA present
(61.1% of those with HRHPV, 84.9% with low-risk HPV). The presence of any HPV4 vaccine
genotype was 42.0% (21.8 with HPV6, 11.5% with HPV11, 12.8% with HPV16, and 6.75% with
HPV18). Coinfection with HPV4 low-risk genotypes (presence of both 6 and 11) was found in
14 participants, whereas coinfection with HPV4 high-risk genotypes (presence of both 16 and
18) was found in six participants. Zero participants had all HPV4 genotypes present.
Of the 571 MSM and TW in the study who completed at least two study visits, 73 (12.8%)
acquired HIV in 2 years, resulting in a 6% HIV incidence rate. Compared to those without
HIV, participants with incident HIV were primarily younger than 25 (52% vs. 46%, p = .039)
and more likely to have reported STI symptoms (44% vs. 29.4%, p = .038), more likely to have
anal bleeding (28% vs. 11%, p = .005), and more likely to have anal ulcers (12% vs. 4%, p =
.016) during the prior 6 months. Additionally, those with incident HIV were less likely to have
used a condom during their most recent anal sex with a man (61% vs. 75%, p = .040), more
likely to have ever had receptive anal intercourse (86% vs. 74%, p = .040), and more likely to
have HRHPV (73% vs. 51%, p = .001). Differences in HPV prevalence (individual HPV types,
HPV4, HPV9) by HIV status are shown in Fig 1.
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Fig 1. HPV prevalence by HIV status among Peruvian MSM and TW.
https://doi.org/10.1371/journal.pone.0204996.g001

We found no statistically significant differences between participants living with HIV and
those without HIV in terms of sexual identity (p = .127), frequency of anal intercourse (p =
.599), overall frequency of anal intercourse without a condom (p = .107), sex under the influence of alcohol (p = .654) or drugs (p = .876) in the prior month, engagement in transactional
sex in the prior 6 months (p = .486), or circumcision status (p = .505).
In multivariate analyses, we adjusted for all statistically significant variables in Table 1.
Model 1 shows the effect of HRHPV on HIV, Model 2 shows the effect of having HPV9 on
HIV, and Model 3 shows the effect of HPV4 on HIV (Table 2). With the other variables remaining constant, the odds of HIV increased in the baseline presence of HRHPV genotypes by 181%
(p = .004), HPV9 genotypes by 144% (p = .011), and HPV4 genotypes by 93% (p = .046). The
odds were highest when the most HPV genotypes were present.
In all three models, condom use during last anal sex with a man remained a protective factor
against HIV infection, whereas anal bleeding was a risk factor. Engaging in receptive anal sex was a
statistically significant risk factor for HIV in Models 1 and 2 and marginally significant in Model 3.

Discussion
The overall annual HIV incidence rate of 6% in the study population is indicative of a troubling, continuing HIV epidemic in Lima, Peru, among MSM and TW. Our finding that participants who acquired HIV were more likely to have HRHPV confirms and extends previous
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Table 2. Logistic regression of HIV status for 571 Peruvian MSM and TW in Peru.
Model 1 (HRHPV)
AOR
HRHPV

2.81

Model 2 (HPV9)
AOR

95% CI

95% CI

1.38, 5.70
2.44

Genotypes in HPV9 vaccine

1.22, 4.87

Genotypes in HPV4 vaccine


Model 3 (HPV4)
AOR

95% CI



1.93

1.01, 3.69
0.21, 0.79

Condom used, last anal sex

0.40

0.20, 0.78

0.40

0.21, 0.78

0.41

Anal bleeding, last 6 months

3.05

1.30, 7.13

2.84

1.23, 6.57

2.77

1.21, 6.34

Sexual role (passive vs. active)

2.67

1.05, 6.77

2.71

1.07, 6.87

2.48

0.98, 6.25

Tertiary education

0.84

0.43, 1.65

0.91

0.47, 1.77

0.91

0.47, 1.78

Age

0.97

0.91, 1.03

0.97

0.91, 1.03

0.97

0.91, 1.03

Pseudo R

10.2

9.4

8.4

Circumcision did not play a role due to the small number of circumcised men with HIV. HRHPV, high-risk HPV; HPV9, 9-valent HPV vaccine; HPV4, 4-valent HPV
vaccine.

p < .05.


p < .01.

https://doi.org/10.1371/journal.pone.0204996.t002

research regarding the significant independent relationship between prevalent HPV (in general) and HIV acquisition among MSM [6]. Although previous work has linked the presence
of unspecified single or two or more HPV genotypes, our work illustrates genotypes specific to
incident HIV, including HRHPV, which can be part of standard testing, and the vaccine genotypes present in HPV9 and HPV4. Consistent with a large body of research, our data also
linked receptive anal sex with risk of HIV acquisition [22].
Other studies have found significant relationships between genital warts, HPV, and multiple HPV infections and HIV-positive status [23,24]. Still, other research explained these relationships as a result of increased immunodeficiency and susceptibility to genital warts and
HPV due to HIV infection [25–28].
This was a nonrandom sample of 600 MSM and TW who met eligibility criteria including
genital wart status and were recruited at gay venues in metropolitan Lima, therefore, it is not
representative of all MSM or TW in Lima. Some participants lost to follow-up at the final visit
could have been HIV-positive, which would have affected our models of HPV and HIV infection. We also measured HPV status at a single point and combined anal and penile specimens
into one combined sample. Retrospective studies can examine the relationship between HPV
and HIV, although temporality may play a role (i.e., which infection, HIV or HPV, occurred
first). Further, while this study found a significant relationship between having HRHPV and
acquiring HIV, the presence of an association does not prove causality. As such, it is important
to consider other explanations for this association. For instance, there may be other behavioral
factors that may have predisposed participants to both HIV and HPV acquisition which we
did not assess, such as sex toy sharing or douching. Further, there may have been biological
reasons that partially explain why some participants were more prone to the acquisition of
HR-HPV and HIV, including bacterial STIs. Lastly, it is possible that some participants were
infected with HIV at baseline but tested negative due to the window period of the assay, and
seroconversion may have driven higher HPV prevalence.

Conclusions
Our findings support other research [6,29] that suggested vaccinating against HRHPV may
have a protective effect against the acquisition of HIV among MSM and TW. Moreover, given
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the strong relationship between HRHPV and head, neck, throat, penile, and anal cancers, and
data showing MSM are at increased risk of such cancers [25], HPV vaccination may benefit
MSM and TW in this understudied population [30].
Although new vaccine adoption often takes more time in lower-resource settings, the HPV
vaccine is currently provided exclusively to school-aged girls in Peru. This may help promote
greater acceptance among vaccine decision makers and help expand coverage to school-aged
boys and adult MSM and transgender individuals [31–33]. Comprehensive awareness-raising
and health education efforts sponsored by the national government, health administrators,
and civil society leaders regarding HPV and its consequences are important to keeping parents
and communities informed, reassuring them the vaccine is safe and effective, and garnering
community acceptance [31,34]. Early HPV vaccination paired with robust HIV prevention
strategies can prevent both HPV related outcomes and incident HIV infection.
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